Neovacs

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. Show More...

  • Website https://www.neovacs.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.00 EUR
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2009-12 2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 TTM
    Earnings Per Share EUR -0.5 -0.65 -0.49 -0.44 -0.34 -0.32 -0.15 -0.31 -0.21 -0.1 -0.06
    Dividends EUR
    Payout Ratio % *
    Shares Mil 14.0 14.0 17.0 16.0 20.0 23.0 31.0 45.0 71.0 108.0 143.0
    Book Value Per Share * EUR 0.62 0.91 0.23 0.36 0.11 0.08 0.18 -0.010 0.010 0.03
    Free Cash Flow Per Share * EUR -0.6 -0.55 -0.38 -0.25 -0.38 -0.29 -0.22 -0.27 -0.2
    Return on Assets % -150.4 -115.72 -67.1 -72.55 -95.58 -87.05 -44.79 -129.92 -135.87 -112.38 -90.33
    Financial Leverage (Average) 1.28 1.22 1.67 2.13 1.59 1.81 5.44 10.67 2.97 1.95
    Return on Equity % -217.91 -83.79 -97.24 -180.9 -156.75 -76.52 -340.39 -606.2 -176.42
    Return on Invested Capital % -139.05 -77.19 -85.07 -141.8 -123.13 -64.86 -280.3 -453.32 -329.1 -172.14
    Interest Coverage -32.17 -62.22 -59.16 -165.21 -173.55 -36.03 -87.1 -89.48
    Current Ratio 5.13 6.91 9.33 4.22 2.59 4.48 2.66 1.27 1.35 1.43 2.03
    Quick Ratio 5.04 6.35 9.07 3.9 2.36 4.21 2.52 1.21 1.27 1.36 1.14
    Debt/Equity 0.08 0.08 0.25 0.3 0.22 0.12 0.44 2.35 0.12 0.010